Rare diseases
Investigational molecules
Locations
Back to Germany534 clinical trials in Freiburg Im Breisgau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)A Study Comparing Nipocalimab and Efgartigimod for Adults with Generalized Myasthenia Gravis
GermanyStudy of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia
GermanyA study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed
GermanyA study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis
GermanyA Study of Belumosudil for Patients with Steroid-Resistant Overlap Syndrome Graft-versus-Host Disease
GermanyTesting Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia
GermanyA Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes
GermanyA Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment
GermanyA Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer
GermanyA Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
GermanyA study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies
GermanyTesting dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease
GermanyThe busiest research cities in the country
What the registry says about research in the country
Neoplasms research in Freiburg covers a broad mix of cancer studies, from lung and colorectal cancer to breast, endometrial, prostate, sarcoma, and childhood leukemia. These trials are mainly focused on testing new treatments, improving cancer control, and refining treatment combinations for better outcomes.
Several studies are evaluating whether new cancer therapies can improve survival, delay recurrence, or support earlier and more effective treatment choices.
Clinical trials in nervous system diseases are examining acute stroke care and childhood cerebrovascular disorders. The research aims to improve recovery after stroke, reduce recurrence, and assess new treatment options for difficult cases.
This area includes studies of thrombolysis and anti-inflammatory treatment strategies designed to improve functional outcomes and neurological recovery.
Freiburg also hosts studies in respiratory tract diseases and neonatal lung care, with a strong focus on preterm infants and oxygen-related support. These trials are evaluating ways to improve breathing outcomes and reduce complications in vulnerable newborns.
In addition to newborn care, lung cancer research is testing whether newer oncology approaches can improve disease control in advanced respiratory malignancies.
A major part of the research landscape in Freiburg is dedicated to congenital, hereditary, and neonatal diseases. These studies focus on safer care for preterm infants, childhood stroke, and pediatric leukemia, with the goal of improving long-term health and survival.
The trials are designed to support better early treatment decisions and to reduce complications that can affect development later in life.
Studies in cardiovascular diseases and chronic kidney disease are exploring ways to slow disease progression and lower the risk of major heart-related events. The goal is to strengthen preventive care for people with long-term metabolic and organ-related conditions.
These trials are looking at whether new treatment combinations can improve long-term safety and reduce complications in high-risk patients.
Trials in hormonal diseases and related metabolic conditions are addressing disorders that affect both quality of life and long-term health. This includes research on hormone-sensitive cancers, lipid disorders, and treatment approaches linked to kidney and heart protection.
The studies aim to improve disease control and better tailor treatment to patients with chronic hormonal or metabolic risk factors.
Research in psychological phenomena includes clinical trials for ADHD in adults. These studies are focused on comparing treatment options that may help improve attention, daily functioning, and symptom control.
This area reflects an interest in evidence-based approaches for managing neurodevelopmental symptoms in adult care.
Freiburg’s clinical trials also include skin and connective tissue diseases, especially hair loss conditions. The research is evaluating new ways to improve hair growth and address androgen-related hair loss in both men and women.
These studies are aimed at finding more effective and better-tolerated options for common hair disorders.
The city’s research portfolio includes otorhinolaryngologic diseases, with trials focused on sudden hearing loss. The main purpose is to assess whether new treatment options can improve hearing recovery more effectively than current care.
This work is especially relevant for rapid intervention in conditions where early treatment may influence long-term hearing outcomes.
Trials in digestive system diseases include research on bowel and rectal complications related to cancer treatment. These studies aim to reduce symptoms and improve comfort for patients undergoing oncologic care.
The focus is on symptom relief and improving quality of life during or after radiotherapy.
Research in male urogenital diseases includes prostate cancer studies and work on hair and hormonal conditions affecting men. The trials are testing whether new treatment strategies can improve disease control and patient well-being.
In Freiburg, this area combines cancer research with supportive care questions that matter for everyday treatment experience.
A smaller set of studies addresses reproductive and urinary physiological phenomena, especially kidney-related health and treatment effects that influence urinary function. These trials are aimed at better protection of organ function over time.
The research reflects growing interest in preserving both cardiovascular and urinary system health in chronic disease.
Several Freiburg trials explore inflammatory mechanisms across different diseases, from stroke-related vessel disease to cancer and radiation injury. The main purpose is to see whether targeted anti-inflammatory or immune-based approaches can improve outcomes.
This field links inflammation research with practical treatment questions in both neurology and oncology.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
